A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lenvatinib (Primary) ; Rifampicin
- Indications Adenocarcinoma; Endometrial cancer; Glioma; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 01 Dec 2013 New trial record
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.